2 news items
Why NKGen Biotech Stock Is Moving Higher Monday
NKGN
20 May 24
another important clinical milestone in our mission to advance SNK01 as the first potential disease modifying treatment of its kind for patients with more
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
milestone in our mission to advance SNK01 as the first potential disease modifying treatment of its kind for patients with more advanced Alzheimer's disease
- Prev
- 1
- Next